GlassScriptPhysician profile
Sharon Jackson
NPI 1992152987
$319.83
in general payments reported to CMS, 2019-2025
13 companies · $3.96 in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $164 · 2020: $60.39 · 2021: $73.36 · 2024: $18.09 · 2025: $3.96.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $60.46 | 2019-2020 | |
| Alydia Health | $60.03 | 2021 | |
| Allergan, INC. | $49.86 | 2019-2020 | |
| Coopersurgical, INC. | $29.26 | 2021-2024 | Paragard T 380a |
| Therapeuticsmd, INC. | $26.60 | 2019 | |
| Millicent US INC | $16.16 | 2019 | |
| Celularity INC. | $16.00 | 2019 | |
| Lupin INC. | $15.79 | 2020 | |
| Glaxosmithkline, LLC. | $13.87 | 2020 | |
| Daiichi Sankyo INC. | $13.49 | 2019 | |
| Abbvie INC. | $12.19 | 2019 | |
| Mayne Pharma Commercial LLC | $6.12 | 2024-2025 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$3.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharon Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.